EGFR and non-small cell lung carcinoma: In a phase II study, 21 advanced NSCLC patients with EGFR-mutated (19 deletions and 21 L858R) were enrolled, and the patients received the combination treatment of nivolumab and erlotinib with 15% ORR and 65% DCR (Hellmann et al., 2017).